Description
Indications
This tablet is indicated for-
- Reduction of neurological damage & accelerates recovery after cerebral stroke
- Minor age-related neurological disorders
- Some visual disorders related to the circulation
- Some disorders of the inner ear related to circulation (hearing loss, dizziness, buzzing sounds in the ear).
-
Pharmacology
Almitrine Bismesylate & Raubasine combines raubasine, a vasodilator; and almitrine, a respiratory stimulant. Raubasine has a adrenolytic activity which is predominantly related to a post-synaptic blocking effect. Furthermore, under conditions of cerebral hypoxia, almitrine causes an increase in the partial pressure of oxygen in arterial blood (Pa02); almitrine causes an increase in the Pa02 and an increase in the oxygen saturation in arterial blood (Sa02), without modifying ventilatory parameters.Dosage & Administration
1 tablet once or twice daily (taken separately, several hours apart), without exceeding 2 tablets per day. Or, as directed by the registered physicians.Interaction
Do not associate with MAO-l (monoamine oxidase inhibitor), Not to be used concurrently with other almitrine-containing preparations.Contraindications
This tablet is contraindicated in patients with hypersensitivity to any of the ingredients of it or severe hepatic impairment.





Reviews
There are no reviews yet.